Primary Hodgkin Lymphoma of the Breast: A Case Report and Literature Review Examining the Use of Different Chemotherapy Regimens.

Autor:	Arrey Agbor DB; Internal Medicine, Richmond University Medical Center, Staten Island, USA., Zafar W; Hematology/Oncology, Richmond University Medical Center, Staten Island, USA., Agyemang EA; Internal Medicine, Newark Beth Israel Medical Center, Newark, USA., Nzeako T; Internal Medicine, Christiana Care Hospital, Newark, USA., Ugwendum D; Internal Medicine, Richmond University Medical Center, Staten Island, USA., Forsah SF; Internal Medicine, Richmond University Medical Center, Staten Island, USA., Kankeu Tonpouwo G; Internal Medicine, Richmond University Medical Center, Staten Island, USA., Pokuaa IO; Internal Medicine, Capital Health Medical Center, Trenton, USA., Grigos A; Internal Medicine, Richmond University Medical Center, Staten Island, USA., Nfonoyim J; Pulmonary and Critical Care, Richmond University Medical Center, Staten Island, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Jul 27; Vol. 16 (7), pp. e65541. Date of Electronic Publication: 2024 Jul 27 (Print Publication: 2024).
DOI:	10.7759/cureus.65541
Abstrakt:	Primary classic Hodgkin lymphoma (HL) of the breast is a rare type of breast disease. The diagnosis is mostly confirmed by an excisional biopsy. The first line of treatment commonly used for Hodgkin lymphoma is doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Our case report is about a 48-year-old lady who was diagnosed with bilateral breast Hodgkin lymphoma following an excisional biopsy and was treated with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD). The patient responded positively after the initiation of the regimen. There is scarce data on the classic Hodgkin lymphoma of the breast, and even with the wide use of first-line treatment using ABVD, the disease is still difficult to manage. Hence, patients with breast masses should be screened for classic HL of the breast, and larger studies are needed to establish specific treatment guidelines concerning HL of the breast to prevent relapse and other complications. Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Arrey Agbor et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu